Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK : A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy ( BSBMTCT )
British Journal of Haematology · 2025
DOI: 10.1111/bjh.20199 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Majid Kazmi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Guy's & St Thomas' NHS Trust, London, UK. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Multiple Sclerosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Autologous haematopoietic stem cell transplantation (AHSCT) has been developed as a treatment for multiple sclerosis (MS) since 1995. The United Kingdom is one of the most active countries performing AHSCT for MS in Europe. We report the UK experience of AHSCT for MS in 364 patients with MS treated with AHSCT between 2002 and 2023. We report transplant‐related mortality (TRM), AHSCT complications and efficacy as defined by expanded disability status scale (EDSS) progression‐free survival (PFS) at 2 years and 5 years. 209 (58%) had relapsing–remitting MS (RRMS) and 130 (36%) had progressive MS. Median EDSS at the time of HSCT was 6.0 (range: 0–9) and duration of disease was 10 years (range: 4–34). TRM was 1.4%, exclusively occurred in patients with advanced baseline disability (median EDSS: 6.5). Epstein–Barr virus (EBV) reactivation occurred in 75.9% of patients where EBV results were reported (235/311). Overall PFS was 83.5% at 2 years post‐HSCT and 62.4% at 5 years. This large study demonstrates the evolution of this one‐off treatment across the United Kingdom, its safety and sustained efficacy in patients with severe/refractory MS. The uneven geographical access is a future consideration in equitable delivery across the UK NHS as the evidence base for AHSCT in MS treatment pathways becomes stronger.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Guy's & St Thomas' NHS Trust, London, UK.
- Department of Brain Sciences, Imperial College London, London, UK.
- Imperial College Healthcare NHS Trust, London, UK.
- King's College Hospital NHS Trust, London, UK.
- Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
- Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
ORCID-Profile: Majid Kazmi, Varun Mehra, John A Snowden
Zitieren
APA
Kazmi, M., Muraro, P. A., Mehra, V., Gabriel, I., De Matteis, E., Brittain, G., Mariottini, A., Nicholas, R., Silber, E., Lee, J., Pearce, R., Paul, R., Sormani, M. P., Signori, A., Potter, V., Olavarria, E., Malladi, R., Sharrack, B., & Snowden, J. A. (2025). Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK : A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy ( BSBMTCT ). British Journal of Haematology. https://doi.org/10.1111/bjh.20199
Vancouver
Kazmi M, Muraro PA, Mehra V, Gabriel I, De Matteis E, Brittain G, et al. Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK : A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy ( BSBMTCT ). British Journal of Haematology. 2025. doi:10.1111/bjh.20199
BibTeX
@article{Kazmi2025,
author = {Kazmi, Majid and Muraro, Paolo A and Mehra, Varun and Gabriel, Ian and De Matteis, Eleonora and Brittain, Gavin and Mariottini, Alice and Nicholas, Richard and Silber, Eli and Lee, Julia and Pearce, Rachel and Paul, Ruth and Sormani, Maria Pia and Signori, Alessio and Potter, Victoria and Olavarria, Eduardo and Malladi, Ram and Sharrack, Basil and Snowden, John A},
title = {Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK : A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy ( BSBMTCT )},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.20199}
}
EUVIMED